← All stocks

Arcutis Biotherapeutics, Inc.

ARQT Mostly scheduled

CIK 0001787306 #1713 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$17.16M

$10.54M on a plan · $5.84M straight out of an exercise

Sold at will

$778.75K

2 of 82 sales

Net

−$17.16M

−$778.75K against sales at will

By person

16 insiders · 82 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Watanabe Todd

See Remarks

—

$5.32M (13) scheduled

−$5.32M

742,613

0.5908%

$18.58M

−8.3%

Welgus Howard G.

Director

—

$2.31M (13) scheduled

−$2.31M

36,475

0.0290%

$912.83K

−81.0%

Matsuda Masaru

See Remarks

—

$2.12M (17) scheduled

−$2.12M

116,182

0.0924%

$2.91M

−38.8%

Burnett Patrick

See Remarks

—

$2.02M (18) scheduled

−$2.02M

117,592

0.0936%

$2.94M

−44.4%

Leonard Keith R

Director

—

$997.19K (1) scheduled

−$997.19K

27,901

0.0222%

$698.25K

+48.2%

Curran Terrie

Director

—

$984.04K (3) scheduled

−$984.04K

23,526

0.0187%

$588.76K

+25.0%

Edwards Larry Todd

See Remarks

—

$968.36K (6)

−$968.36K

175,178

0.1394%

$4.38M

+23.5%

Krishnamohan Neha

Director

—

$939.49K (2) scheduled

−$939.49K

27,901

0.0222%

$698.25K

+77.2%

LIN SUE-JEAN

Director

—

$898.54K (2) scheduled

−$898.54K

27,567

0.0219%

$689.89K

+44.1%

Gilbert Halley E

Director

—

$455.44K (1) scheduled

−$455.44K

27,901

0.0222%

$698.25K

+48.2%

Vairavan Latha

SVP Chief Financial Officer

—

$148.50K (6) scheduled

−$148.50K

85,978

0.0684%

$2.15M

+90.6%

CHAUDHURI BHASKAR

Director

—

867,826

0.6904%

$21.72M

+0.9%

Topper David Joseph

Chief Financial Officer

—

182,774

0.1454%

$4.57M

+66.2%

Heron Patrick J

Director

—

59,661

0.0475%

$1.49M

+216.9%

Munshi Amit

Director

—

9,799

0.0078%

$245.23K

+390.0%

Peetz Christopher

Director

—

4,315

0.0034%

$107.99K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 66

Amendments (4/A) skipped 1

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 63

Sales straight out of an exercise 17

Sales at will 2

Transactions with no price 0

Shares from compensation/vesting 503,756

History held since 3 Feb 2020